Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × birinapant × Clear all
NCT01188499 2016-05-30

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

TetraLogic Pharmaceuticals

Phase 1/2 Completed
176 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00993239 2016-03-03

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

TetraLogic Pharmaceuticals

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT01940172 2016-01-14

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

TetraLogic Pharmaceuticals

Phase 1 Completed
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡